Sekeres, Mikkael A. http://orcid.org/0000-0003-2009-6524
Watts, Justin
Radinoff, Atanas
Sangerman, Montserrat Arnan
Cerrano, Marco http://orcid.org/0000-0003-1666-3100
Lopez, Patricia Font http://orcid.org/0000-0002-9738-4930
Zeidner, Joshua F. http://orcid.org/0000-0002-9014-1514
Campelo, Maria Diez http://orcid.org/0000-0002-1467-6779
Graux, Carlos
Liesveld, Jane
Selleslag, Dominik
Tzvetkov, Nikolay
Fram, Robert J.
Zhao, Dan
Bell, Jill
Friedlander, Sharon
Faller, Douglas V. http://orcid.org/0000-0002-2454-3478
Adès, Lionel
Funding for this research was provided by:
Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
Article History
Received: 27 July 2020
Revised: 24 November 2020
Accepted: 7 January 2021
First Online: 22 January 2021
Change Date: 17 November 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41375-021-01473-1
Compliance with ethical standards
:
: MAS reports a membership or advisory role for Takeda/Millennium and Bristol-Myers Squibb. JW reports consulting for Jazz Pharmaceuticals, Takeda, Genentech, Rafael Pharma, Pfizer, and Celgene. AR reports consultancy within the past two years for Janssen, Pfizer, Novartis, Servier, research funding from Amgen, Bayer, Takeda, and honoraria directly received from an entity from Janssen, Pfizer, Novartis, and Servier. MAS reports consulting and research funding from Novartis and Celgene and research funding from Janssen. PFL reports expert testimony for Celgene and Novartis, and an advisory board role for Celgene, Pfizer, and Menarini. JFZ reports consultancy, researching funding, and honoraria from Celgene and Takeda, consultancy from AsystBio Laboratories, and research funding from Arog Pharmaceuticals Inc., Forty Seven, Inc., Merck, and Tolero Pharmaceuticals, Inc. JFZ also reports honoraria from AbbieVie, Agios, Daiichi Sankyo, Genentech, and Pfizer. MDC reports a membership or advisory role and consulting for Celgene, Novartis, and Takeda. CG reports an advisory board role for Celgene, Pfizer, Novartis, Janssen, Incyte, and Amgen. DS reports consultancy and honoraria from Takeda, Celgene, Novartis, Janssen Cilag, and AbbVie, expert testimony from Celgene and Janssen Cilag, and membership or advisory role for Belgian College for reimbursement of orphan drugs. RJF reports employment for Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, consultancy for BeyondSpring Pharmaceuticals, and an ownership interest in Takeda, Bristol Myers Squibb, Teva, Baxter, Gilead Sciences, and Pfizer. DZ, SF, and DVF report employment for Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited. JB reports employment and an ownership interest in Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited. LA reports honoraria directly received from an entity from Celgene, Takeda, Abbvie, and Jazz Pharmaceuticals. The remaining authors declare that they have no conflict of interest.